الخَرَف

إعداد فريق مايو كلينك
16 سبتمبر 2026

الأبحاث

ينخرط الباحثون في مايو كلينك في دراسة مرض الخرف والعمل على تطوير آليات تشخيص هذا الاضطراب وسبل علاجه. يمكن أن تتاح لك المشاركة في تجربة سريرية في مايو كلينك ضمن خطتك العلاجية.

المنشورات

راجع قائمة المنشورات التي أعدّها أطباء مايو كلينك حول الخَرَف على محرك البحث PubMed، وهي خدمة تقدمها المكتبة الوطنية الأمريكية للطب.

  1. What is dementia? Alzheimer's Association. https://www.alz.org/alzheimers-dementia/what-is-dementia. Accessed April 24, 2023.
  2. Dementias. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Dementia-Hope-Through-Research. Accessed April 24, 2023.
  3. Larson EB. Evaluation of cognitive impairment and dementia. https://www.uptodate.com/contents/search. Accessed April 24, 2023.
  4. Rao RV, et al. Rationale for multi-factorial approach for the reversal of cognitive decline in Alzheimer's disease and MCI: A review. International Journal of Molecular Sciences. 2023; doi:10.3390/ijms24021659.
  5. Press D, et al. Management of the patient with dementia. https://www.uptodate.com/contents/search. Accessed April 24, 2023.
  6. Livingston G, et al. Dementia prevention, intervention and care: 2024 report of the Lancet standing Commission. The Lancet. 2024; doi:10.1016/S0140-6736(24)01296-0.
  7. Luo G, et al. Effectiveness of non-pharmacological therapies on cognitive function in patients with dementia — A network meta-analysis of randomized controlled trials. Frontiers in Aging: Neuroscience. 2023; doi:10.3389/fnagi.2023.1131744.
  8. Clinical overview of Creutzfeldt-Jakob disease (CJD). Centers for Disease Control and Prevention. https://www.cdc.gov/creutzfeldt-jakob/hcp/clinical-overview/. Accessed Jan. 24, 2025.
  9. Palimariciuc M, et al. The quest for neurodegenerative disease treatment — Focusing on Alzheimer's disease personalised diets. Current Issues in Molecular Biology. 2023; doi:10.3390/cimb45020098.
  10. Dementia. Merck Manual Professional Version. https://www.merckmanuals.com/professional/neurologic-disorders/delirium-and-dementia/dementia. Accessed Jan. 24, 2025.
  11. Press D, et al. Prevention of dementia. https://www.uptodate.com/contents/search. Accessed April 24, 2023.
  12. Sleep issues and sundowning. Alzheimer's Association. https://www.alz.org/help-support/caregiving/stages-behaviors/sleep-issues-sundowning. Accessed May 2, 2023.
  13. Medications for memory. Alzheimer's Association. https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory. Accessed April 24, 2023.
  14. How to communicate with a person with dementia. Alzheimer's Society. https://www.alzheimers.org.uk/about-dementia/symptoms-and-diagnosis/symptoms/tips-for-communicating-dementia. Accessed April 24, 2023.
  15. Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023; doi:10.1001/jama.2023.13239.
  16. Leqembi (prescribing information). Eisai; 2023. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761269. Accessed Feb. 2, 2025.
  17. Lecanemab approved for treatment of early Alzheimer's disease. Alzheimer's Association. https://www.alz.org/alzheimers-dementia/treatments/lecanemab-leqembi. Accessed Jan. 24, 2024.
  18. Van Dyck CH, et al. Lecanemab in early Alzheimer's disease. The New England Journal of Medicine. 2023; doi:10.1056/NEJMoa2212948.
  19. Kornblith E, et al. Traumatic brain injury, cardiovascular disease and risk of dementia among older US veterans. Brain Injury. 2022; doi:10.1080/02699052.2022.2033842.
  20. Cummings J, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimer's and Dementia. 2022; doi:10.1002/trc2.12295.
  21. Oxybutynin oral. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed April 28, 2023.
  22. Diphenhydramine oral. Facts & Comparisons eAnswers. https://fco.factsandcomparisons.com. Accessed April 28, 2023.
  23. Kang C. Donanemab: First approval. Drugs. 2024; doi:10.1007/s40265-024-02087-4.
  24. Budson AE, et al. Cholinesterase inhibitors. In: Memory Loss, Alzheimer's Disease, and Dementia. 3rd ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed May 4, 2023.
  25. Kisunla (prescribing information). Eli Lilly and Company; 2024. https://www.lilly.com/. Accessed Feb. 2, 2025.
  26. Lopez-Ortiz S, et al. Effects of physical activity and exercise interventions on Alzheimer’s disease: An umbrella review of existing meta-analyses. Journal of Neurology. 2023; doi:10.1007/s00415-022-11454-8.
  27. Nimmagadda R. Allscripts EPSi. Mayo Clinic. Jan. 13, 2025.
  28. Batubara SO, et al. Effects of art therapy for people with mild or major neurocognitive disorders: A systematic review and meta-analysis. Archives of Psychiatric Nursing. 2023; doi:10.1016/j.apnu.2023.04.011.
  29. Yin Z, et al. Comparative efficacy of multiple non-pharmacological interventions for behavioural and psychological symptoms of dementia: A network meta-analysis of randomized controlled trials. International Journal of Mental Health Nursing. 2024; doi:10.1111/inm.13254.
  30. Chen H, et al. Effects of animal-assisted therapy on patients with dementia: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Research. 2022; doi:10.1016/j.psychres.2022.114619.
  31. Leqembi (prescribing information). Eisai; 2025. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761269. Accessed Feb. 9, 2025.
  32. Alzheimer’s disease genetics fact sheet. National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/alzheimers-disease-genetics-fact-sheet#. Accessed Feb. 9, 2025.
  33. Rafii MS, et al. The AHEAD-3-45 study: Design of a prevention trial for Alzheimer’s disease. Alzheimer's & Dementia. 2023; doi:10.1002/alz.12748.